Metastatic prostate cancer is currently associated with high morbidity and mortality rates. In addition, patients respond very differently to standard treatments such as hormone therapy or radiation ...

New research has identified specific blood-based biomarkers that can predict the failure of prostate cancer treatment in both hormone-sensitive and castration-resistant patients. The study published ...

A new study led by researchers at The University of Texas MD Anderson Cancer Center found that prostate cancer patients with low testosterone levels may have a higher risk of cancer progressing to a ...

A new research paper was published in Volume 13 of Oncoscience on February 7, 2026, titled “Reduced immunogenicity of MYC amplified, metastatic prostate cancer.” ...

PSMA PET scans significantly enhance detection and staging of prostate cancer, improving patient stratification and survival outcomes. Three FDA-approved PSMA PET scans are available, aiding in both ...

Prostate cancer is one of the most common cancers affecting men around the world. In many countries, including Germany, it is the most frequently diagnosed cancer in men. Each year, about 65,000 men ...

They retain early prostate cancer genomic aberrations and often acquire tumor suppressor losses (eg, TP53, RB1) and distinct changes in their epigenetic and transcriptomic landscape. 71 The most ...